Key Considerations When Integrating an End-To-End Single-Use mAbs Production Facility

InfoWeb Marketplace

Friday, May 17, 2019Description :
In an exclusive interview with Miriam Monge, Head of Segment Marketing mAb at Sartorius, Nienke Vriezen, Synthon’s Director of USP Development and Manufacturing, talks about how Sartorius helped Synthon to rapidly implement a flexible single-use facility for the manufacture of monoclonal antibodies. Founded in 1991, Synthon now employs 1,700 people at nine sites worldwide. The company develops biopharmaceuticals with a focus is on next-generation cancer drugs.

Grouped quotes (0)